Corvus Pharma Com (CRVS) Stock Price, Quote & News

Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psori...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 900 4520

Website: www.corvuspharma.com

Address:

901 Gateway Boulevard, Third Floor, South San Francisco, United States

Jellysquid1 Dec. 28 at 7:54 PM

$CRVS IN 2026 People Expecting 👇👇👇

1 · Reply

tradingjunk321 Dec. 27 at 6:27 PM

$CRVS Smart person, although I think it will be a ten bagger within a year or two (not to or too ABC 😂).

0 · Reply

KingKai2020 Dec. 26 at 4:38 PM

$CRVS “Johnson & ⁠Johnson said ‍it ‍discontinued ‌a ‌mid-stage study of its experimental drug ⁠to treat atopic dermatitis, after it ‍failed to ‌meet ⁠efficacy goals.” ”Pharmacyclics and Janssen (a J&J company) partnered in 2011 to develop and sell ibrutinib (Imbruvica), sharing costs, development, and profits globally for this cancer drug, with Janssen handling ex-US sales and sharing US efforts with Pharmacyclics before AbbVie acquired Pharmacyclics in 2015” Miller & J&J have danced in the past. given rhe size of rhe dermatitis market I am sure they will be watch the January read out.

2 · Reply

biotech_loser Dec. 26 at 3:27 PM

$CRVS Johnson & Johnson halts mid-stage trial of experimental eczema drug https://www.cnbc.com/2025/12/26/johnson-johnson-halts-mid-stage-trial-of-experimental-eczema-drug.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension

0 · Reply

1iquid Dec. 26 at 3:31 AM

💎 Liquid® Live Actionable Trade Asset: $CRVS Contracts: $CRVS July 17, 2026 $8 Calls Scale in: $2.21- $2.70 Scale out: $8.60-$14.75 Profit Potential : 312% ROI Blended Join 💎 Here: https://1iquid.com

0 · Reply

dwsrph1 Dec. 26 at 2:34 AM

$CRVS Old dwscottrph1 ain’t doing so bad!!!

1 · Reply

tradingjunk321 Dec. 25 at 8:17 PM

$CRVS Merry Christmas, 2026 could be our year 🤞, Moore to come!

1 · Reply

BillionerOfKing Dec. 25 at 9:31 AM

$CRVS Current Stock Price: $7.47 Contracts to trade: $5 CRVS Jan 16 2026 Call Entry: $2.80 Exit: $4.10 ROI: 46% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

IntrinsicValueI Dec. 25 at 7:51 AM

$CRVS Risk premia compress only when proof accumulates, given the heightened sensitivity to timeline slippage. Momentum turns durable only after multiple confirmations.

0 · Reply

Jellysquid1 Dec. 24 at 2:13 PM

$CRVS

0 · Reply

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:01 PM EST - 7 weeks ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Oct 31, 2025, 7:30 AM EDT - 2 months ago

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 28, 2025, 4:01 PM EDT - 2 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Oct 17, 2025, 10:00 AM EDT - 2 months ago

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Oct 2, 2025, 4:01 PM EDT - 3 months ago

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Aug 12, 2025, 11:31 PM EDT - 4 months ago

Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts

Aug 8, 2025, 3:20 PM EDT - 5 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 5 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Jun 4, 2025, 7:00 AM EDT - 7 months ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 28, 2025, 4:01 PM EDT - 7 months ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 9, 2025, 11:57 AM EDT - 8 months ago

Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

May 8, 2025, 11:06 PM EDT - 8 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:02 PM EDT - 8 months ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 8 months ago

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Apr 23, 2025, 4:08 PM EDT - 8 months ago

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Apr 9, 2025, 4:01 PM EDT - 9 months ago

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Mar 28, 2025, 9:30 AM EDT - 9 months ago

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

Mar 28, 2025, 9:29 AM EDT - 9 months ago

Corvus Pharmaceuticals: Now At Cruising Altitude

Mar 25, 2025, 7:58 PM EDT - 9 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 4:01 PM EDT - 9 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 8:00 AM EDT - 10 months ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 19, 2025, 4:01 PM EDT - 10 months ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 17, 2025, 4:01 PM EDT - 10 months ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 12, 2025, 8:00 AM EDT - 10 months ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Feb 4, 2025, 8:00 AM EST - 11 months ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 13, 2025, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 7, 2025, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 1:36 PM EST - 1 year ago

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Dec 18, 2024, 1:23 PM EST - 1 year ago

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Dec 18, 2024, 8:42 AM EST - 1 year ago

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HEI TSLA

Dec 18, 2024, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 17, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 4, 2024, 4:05 PM EST - 1 year ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Nov 14, 2024, 10:01 AM EST - 1 year ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 13, 2024, 1:18 PM EST - 1 year ago

Corvus Pharmaceuticals: The Market Likes The Story

Nov 13, 2024, 12:02 AM EST - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 9, 2024, 1:40 PM EST - 1 year ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Nov 5, 2024, 4:02 PM EST - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

$Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma$

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 7:03 AM EDT - 1 year ago

Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL

Aug 9, 2024, 10:22 PM EDT - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

$Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)$

Aug 1, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Jun 20, 2024, 6:53 AM EDT - 1 year ago

Corvus Pharmaceuticals Is Ready To Take Flight

May 30, 2024, 4:02 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

Jellysquid1 Dec. 28 at 7:54 PM

$CRVS IN 2026 People Expecting 👇👇👇

1 · Reply

tradingjunk321 Dec. 27 at 6:27 PM

$CRVS Smart person, although I think it will be a ten bagger within a year or two (not to or too ABC 😂).

0 · Reply

KingKai2020 Dec. 26 at 4:38 PM

2 · Reply

biotech_loser Dec. 26 at 3:27 PM

0 · Reply

1iquid Dec. 26 at 3:31 AM

0 · Reply

dwsrph1 Dec. 26 at 2:34 AM

$CRVS Old dwscottrph1 ain’t doing so bad!!!

1 · Reply

tradingjunk321 Dec. 25 at 8:17 PM

$CRVS Merry Christmas, 2026 could be our year 🤞, Moore to come!

1 · Reply

BillionerOfKing Dec. 25 at 9:31 AM

0 · Reply

IntrinsicValueI Dec. 25 at 7:51 AM

$CRVS Risk premia compress only when proof accumulates, given the heightened sensitivity to timeline slippage. Momentum turns durable only after multiple confirmations.

0 · Reply

Jellysquid1 Dec. 24 at 2:13 PM

$CRVS

0 · Reply

TheLeverageLink Dec. 24 at 12:16 PM

$CRVS The next phase will be defined by how strategic priorities translate into measurable operating outcomes. Long-term optimism depends on disciplined follow-through.

0 · Reply

tradingjunk321 Dec. 23 at 10:07 PM

$CRVS anyone know anything about this? Moore to come!

0 · Reply

elmono Dec. 23 at 9:56 PM

$CRVS continues to sink. Short volume increasing last week. Wonder when we see any updated filings on tutes decreasing positions…..not looking pretty

2 · Reply

Jellysquid1 Dec. 23 at 9:42 PM

$CRVS In case you didn't know

0 · Reply

Jellysquid1 Dec. 23 at 7:57 PM

$CRVS Bought Some Moore! This will be us in January 😀😀

0 · Reply

Jellysquid1 Dec. 23 at 7:24 PM

$CRVS Im going to have to buy some more Crvs and gift Myself for Xmas!

2 · Reply

dwsrph1 Dec. 23 at 6:26 PM

$CRVS Med Doc just prior to performing a rectum surgery at 6 am today. All went as expected!!🙄

1 · Reply

dwsrph1 Dec. 23 at 6:23 PM

$CRVS

0 · Reply

dwsrph1 Dec. 23 at 6:15 PM

$CRVS @MedicalDoctorInvestor @Jellysquid1 @tradingjunk321 Merry Christmas to you all! I hope the New Year finds you Blessed with wealth and good health. And yes, Med Dic, that goes out to you (moron 🤣)

1 · Reply

Jellysquid1 Dec. 23 at 5:32 PM

$CRVS Atopic Dermatitis data , JP Morgan healthcare conference all Arriving ThIs January! Selling Now would be a losing proposition ! Put some CRVS shares into your family stockings this Xmas!

1 · Reply

dwsrph1 Dec. 23 at 5:31 PM

$CRVS I don’t see us doing too much over the next few weeks. But, we will pop soon! So hold tight longs and send Med Dic a fire extinguisher for Christmas. He will need it for that cyber crap battery under his ass!

0 · Reply

dwsrph1 Dec. 23 at 4:52 PM

$CRVS Drop some more I’ll buy some more Will end up with Moore.

0 · Reply

Market Cap	575.05M
Revenue (ttm)	0.00
Net Income (ttm)	-62.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,351,800
Avg Vol	1,261,748
Day's Range	N/A - N/A
Shares Out	74.68M
Stochastic %K	31%
Beta	0.64
Analysts	Strong Sell
Price Target	$15.33